IMMUNE THERAPEUTICS, INC.
ANNOUNCES FIRST SALES & SHIPMENT
OF LODONAL;
RECEIVES TRADEMARK AND PATENT APPROVAL
FROM FEDERAL REPUBLIC OF NIGERIA
Orlando, FL --
February 20, 2018 -- InvestorsHub
NewsWire -- Immune Therapeutics,
Inc. (OTCQB:IMUN)
("Immune" "IMUN"
or the
"Company"), a clinical late stage biopharmaceutical company focused
on the development of two immunomodulating therapies (IRT-103
"Lodonal" and IRT-101 "MENK") for the treatment of autoimmune
diseases, inflammatory diseases, cancer and HIV/AIDs, today
announced the company has
shipped its initial order of Lodonal to AHAR Pharma in
Nigeria.
In
addition, IMUN has received both
trademark and patent approval from the Federal Republic of Nigeria
giving the Company
ironclad
protection of its ideas, inventions, designs, and trade secrets
while also ensuring IMUN legal rights are not infringed
upon.
Immune
Therapeutics shipped 100,000 capsules of
Lodonal fulfilling the initial purchase order for $195,000 with
AHAR Pharma, Immune's agent and distributor in Nigeria.
Since the
company's shipment has recently cleared customs, it is now
available via AHAR in Nigeria.
The
company has received a Certificate of Patent Approval for Lodonal
NG/P/2017/602 and Certificate of Registration of Design (Trademark,
Name, Box Design) NG/D.2017/603.
CEO
Noreen Griffin states, "The initial Lodonal order to Nigeria is
just the beginning for us with many more to
come based on our strong relationship with AHAR and our ability
to expand our reach in
the African country through a number of potential
sub-distributors for sales and
marketing."
"While
we are focused on an aggressive marketing strategy of Lodonal in
Nigeria it is vital for us to register and protect our intellectual
property rights there as well especially due to the fact that we
are a non-Nigerian business desiring to take a slice of the almost
200 Million strong import-dependent domestic market which Nigeria
represents. We also believe it forestalls potential pirating and
counterfeiting of our products as well."
"Immune and AHAR are
currently completing the necessary regulatory paperwork for
presentation to the National Agency for Food and Drug
Administration and Control (NAFDAC) for the approval of Lodonal for
a number of additional indications."
Griffin said she
believes the company will be ready to submit to NAFDAC in Q1 of
2018.
The
company plans to meet this month with AHAR, GB Pharma and Fidson
HealthCare as a follow up to their initial meeting in October,
2017. The companies plan to further discuss the potential for the
transfer of distributorship from AHAR to Fidson. Under a potential
new agreement, AHAR would remain Immune's agent in
Nigeria.
About
Immune Therapeutics, Inc.
Immune
Therapeutics Inc., is a late stage, Biotechnology Company focused
on the development and commercialization our highly innovative
immunotherapies for the treatment the treatment of HIV/AID's,
cancer and autoimmune and inflammatory disease. Our proprietary and
patented therapies combat these diseases by activating and/or
rebalancing the immune system.
IMUN's
drug discovery are based on two interrelated
immunotherapies that are patented, licensed to the Company and our
lead candidate Lodonal is a repurposed drug. Lodonal has
demonstrated success versus other drug platforms having already
achieved strong validation
with regulatory drug approval in Nigeria and Dominican Republic. .
The National Agency for Food and Drug Administration and Control
(NAFDAC) is a Nigerian federal agency under the Federal Ministry of
Health of Nigeria granted drug and marketing
approval as a immune system
regulator in the management of HIV patients. The Directorate
General of Drugs & Pharmaceuticals, under the Ministry of
Public Health in the Dominican Republic approved Lodonal for the
treatment of HIV/AID's, Cancer and
other immune dysfunction. The Company believes that these approvals
will allow us to shortly begin commercialization in these
countries. In addition IMUN has filed for New Drug Approval in
Kenya, Senegal and Haiti and hopes to have approval by the end of
2017 in at least one of these countries.
While
traditional drug development targets each drug to a particular
disease, such as drug A for disease A, drug B for disease B, etc.,
we are approaching the process by identifying and targeting
survival or activation immunology pathways that cross over between
different diseases. Our lead product Lodonal shows the success of
this model.
Forward-Looking
Statements
This
release may contain forward-looking statements. Actual results may
differ from those projected due to a number of risks and
uncertainties, including, but not limited to, the possibility that
some or all the matters and transactions considered by the Company
may not proceed as contemplated, and by all other matters specified
in the Company's filings with the Securities and Exchange
Commission. These statements are made based upon current
expectations that are subject to risk and uncertainty. The Company
does not undertake to update forward-looking statements in this
news release to reflect actual results, changes in assumptions or
changes in other factors affecting such forward-looking
information. Assumptions and other information that could cause
results to differ from those set forth in the forward-looking
information can be found in the Company's filings with the
Securities and Exchange Commission (www.sec.gov), including its
recent periodic reports.
CONTACT:
888-613-8802
http://www.immunetherapeutics.com/